Few stories in modern drug development begin with an anonymous underground pamphlet, a manual typewriter and a desert toad.
Yet the modern pharmaceutical race to develop 5-MeO-DMT can be traced back to exactly that.
Today, pharmaceutical companies are investing billions of dollars into developing synthetic 5-MeO-DMT therapies for mental health disorders. Clinical trials are underway around the world, investors are backing psychedelic biotechnology companies, and regulators are beginning to evaluate entirely new treatment models.
The clearest sign yet that 5-MeO-DMT has entered the pharmaceutical mainstream came in July 2026, when Eli Lilly agreed to acquire AtaiBeckley in a transaction worth up to US$3.8 billion. The landmark deal represented the largest pharmaceutical acquisition yet centred on a psychedelic medicine and signalled that one of the world’s biggest drugmakers now viewed 5-MeO-DMT as a strategically important neuroscience asset.
But decades before boardrooms, patents and billion-dollar acquisitions, there was a man named Ken Nelson.
Most people knew him only as Albert Most.
The Scientific Discovery
The story begins in the early 1960s.
Scientists studying naturally occurring psychoactive compounds identified 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in several plant species and, most significantly, within the defensive venom secreted by the Sonoran Desert toad, then known as Bufo alvarius and now classified as Incilius alvarius.
Chemists recognised the molecule as structurally related to DMT but with distinctly different pharmacological properties. While the psychedelic experience was dramatically shorter than LSD or psilocybin, early reports suggested it could produce exceptionally intense experiences characterised by profound ego dissolution and mystical-type states.
Outside scientific circles, however, almost nobody paid attention.
The compound remained little more than a chemical curiosity discussed in academic journals. Few imagined it would one day underpin a new generation of psychiatric medicines.
Enter Ken Nelson
Somewhere in Arizona, an independent researcher had become fascinated by the unusual amphibian that inhabited the Sonoran Desert.
Ken Nelson was not a university professor or a pharmaceutical scientist. He was a self-taught naturalist with an insatiable curiosity about psychoactive plants, fungi and naturally occurring compounds.
Friends described him as meticulous and deeply knowledgeable. Rather than seeking academic recognition, Nelson preferred to work independently, documenting observations that often fell outside mainstream scientific interest.
His greatest fascination became the Sonoran Desert toad.
During the brief monsoon season, the amphibians emerged from underground burrows to breed. When threatened, they secreted a milky white venom from large parotoid glands behind their eyes. Nelson became convinced these secretions represented one of nature’s most extraordinary psychoactive discoveries.
He spent years observing the species, documenting its behaviour and learning how the venom could be collected without harming the animal.
The knowledge he accumulated would eventually find its way onto paper.
Albert Most
Rather than publishing under his own name, Nelson adopted the pseudonym Albert Most.
In 1983, sitting before a manual typewriter, he wrote what would become one of the most influential underground publications in psychedelic history.
Its title was simple:
Bufo Alvarius: The Psychedelic Toad of the Sonoran Desert.
The booklet was modest in appearance but extraordinary in its influence.
It described the biology of the toad, explained the chemistry of its venom and provided practical guidance on collecting and drying the secretion for vaporisation.
Before the internet, this was revolutionary.
Photocopied and distributed throughout underground psychedelic networks, the pamphlet spread across North America before eventually reaching readers around the world. For many people, it became their first introduction to both the Sonoran Desert toad and 5-MeO-DMT.
The publication transformed an obscure amphibian into one of the most talked-about organisms in psychedelic culture.
The Rise of “Toad Medicine”
Throughout the 1990s, knowledge of the Sonoran Desert toad continued to spread through underground communities.
Retreat facilitators incorporated what became known as “toad medicine” into ceremonial settings, while psychonauts described experiences unlike those produced by other psychedelics.
Where psilocybin and LSD often unfolded over many hours, inhaled 5-MeO-DMT typically lasted just 15 to 30 minutes, yet participants frequently described it as among the most profound experiences of their lives.
As interest grew, so too did concerns.
Increasing demand for toad venom prompted conservationists to warn that growing popularity could place unnecessary pressure on wild populations and fragile desert ecosystems. While experienced practitioners advocated collecting secretions without harming the animals, many researchers argued that synthetic 5-MeO-DMT offered an ethical and scientifically preferable alternative by eliminating the need to harvest venom altogether.
That debate would ultimately help shape the future of pharmaceutical development.
Science Returns
By the early 2000s, psychedelic research was slowly re-emerging after decades of prohibition.
Universities reopened research programmes. Governments approved carefully controlled clinical trials. Researchers began investigating whether psychedelic compounds could treat depression, PTSD, addiction and anxiety.
Among the compounds attracting increasing attention was 5-MeO-DMT.
Unlike naturally harvested venom, laboratory-produced synthetic 5-MeO-DMT offered pharmaceutical-grade purity, consistent dosing and freedom from conservation concerns.
The molecule itself—not the toad—became the focus.
Researchers also recognised another significant advantage. Unlike psilocybin, which typically requires six to eight hours of supervised therapy, 5-MeO-DMT produces a much shorter psychedelic experience. If clinical trials continue to demonstrate safety and efficacy, this shorter treatment window could make psychedelic-assisted therapy considerably easier to integrate into mainstream healthcare systems.
Early studies suggested the compound may produce rapid improvements in depression, anxiety and psychological wellbeing. While much larger clinical trials remain necessary, pharmaceutical companies, clinicians and investors were all paying close attention.
Beckley Psytech Changes the Conversation
As clinical evidence strengthened, biotechnology companies began asking whether 5-MeO-DMT could become an approved medicine rather than remain an underground psychedelic.
Among the companies leading that transition was Beckley Psytech.
Founded to develop short-acting psychedelic medicines for neurological and psychiatric disorders, the company focused on BPL-003, a proprietary intranasal formulation of synthetic 5-MeO-DMT.
Rather than relying on naturally sourced venom, Beckley developed a pharmaceutical-grade therapy manufactured under strict clinical standards.
Its objective was clear: create a medicine capable of delivering the therapeutic potential associated with 5-MeO-DMT while meeting the safety, consistency and regulatory standards required by modern healthcare systems.
Early clinical data suggested rapid antidepressant effects alongside a treatment duration that could fit within routine clinical practice.
Compared with six to eight-hour psilocybin sessions, the commercial implications were substantial.
From Beckley to Eli Lilly
Momentum accelerated in 2025 when atai Life Sciences acquired Beckley Psytech in an all-share transaction valued at approximately US$390 million, combining Beckley’s clinical programmes with atai’s broader mental health drug development platform to create AtaiBeckley.
The merger gave the combined company one of the strongest pipelines in psychedelic medicine, centred on BPL-003 and a growing portfolio of next-generation psychiatric therapies.
Less than a year later, the industry’s trajectory changed again.
In July 2026, Eli Lilly announced it would acquire AtaiBeckley for approximately US$2.8 billion upfront, with a further US$1 billion tied to development and regulatory milestones, valuing the transaction at up to US$3.8 billion.
The acquisition represented far more than another biotechnology deal.
It marked the strongest commercial endorsement yet of 5-MeO-DMT as a pharmaceutical platform and demonstrated that one of the world’s largest drug manufacturers believed psychedelic medicines had become a strategically important area of neuroscience.
Less than half a century after Albert Most typed his underground booklet, one of the compounds he helped introduce to the wider world had become the centrepiece of a multi-billion-dollar pharmaceutical acquisition.
The journey from desert curiosity to institutional investment was complete.
From Underground Curiosity to Modern Medicine
Ken Nelson never intended to help launch a pharmaceutical industry.
Writing under the pseudonym Albert Most, he simply documented a remarkable natural phenomenon that fascinated him. His pamphlet introduced thousands of people to the Sonoran Desert toad and played a pivotal role in bringing 5-MeO-DMT into the consciousness of the psychedelic underground.
More than forty years later, the conversation has shifted dramatically.
Modern clinical research no longer focuses on harvesting venom from wild amphibians. Instead, scientists are developing pharmaceutical-grade synthetic 5-MeO-DMT that can be manufactured consistently, studied rigorously and, if approved, prescribed safely within modern healthcare systems.
Albert Most could never have predicted that the booklet he typed in 1983 would help introduce the world to a molecule now attracting billions of dollars in pharmaceutical investment.
Yet his story illustrates how scientific breakthroughs often follow unexpected paths.
Sometimes they begin not inside multinational laboratories or corporate boardrooms, but with one curious individual asking questions that nobody else thought to ask.
